Roivant Sciences President & Immunovant CEO Sells $7.32M in Common Shares Under 10b5-1 Plan

Executive Summary

On October 30, 2026, Roivant Sciences Ltd. ($ROIV) disclosed via Form 4 that Eric Venker, President and Immunovant CEO, sold 200,000 Common Shares on October 28, 2026. The transaction generated approximately $7.32 million in gross proceeds at a weighted average price of $36.59 per share.

Transaction Details

• Security: Common Shares
• Transaction Code: S (Open market sale)
• Shares Sold: 200,000 shares
• Execution Price: $36.59 per share (executed in multiple lots ranging from $36.18 to $36.95)
• Total Value: $7,318,000.00
• Post-Transaction Beneficial Ownership: 1,199,154 shares held directly
• Trading Plan: Executed pursuant to a Rule 10b5-1 trading plan established on June 30, 2026

Market & Strategic Context

• Ownership Reduction: The sale represents approximately 14.3% of Dr. Venker's direct common stock position prior to the transaction (1,399,154 shares), leaving him with a substantial remaining direct holding of nearly 1.2 million shares.
• Pre-Scheduled Nature: Because the transaction occurred under a pre-established Rule 10b5-1 plan adopted approximately four months earlier, it reflects scheduled liquidity and diversification rather than an ad hoc response to short-term company developments.